Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Emerging Growth Markets Growth (% cc) by Quarter
Emerging Growth Markets Growth (% cc) (%)
Novartis Emerging Growth Markets Growth (% cc): 8.0% in Q3 2026, up 3.0 pts from a year earlier.
Latest, Q3 2026
8.0%
Period ended Sep 30, 2026
Change on a year earlier
+3.0 pts
5.0% in Q3 2025
History
26 quarters
Since Q2 2020
Sources
26
Documents cited below
Where the Q3 2026 figure comes from
“|| Of which in emerging growth markets | 3 783 | 3 420 | 11 | 8 | 26 | 25”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Emerging Growth Markets Growth (% cc) (%), quarterly Q2 2020–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/geo-emerging-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.